tential future patient. “When we say we need to communicate with them, that’s us.” Public engagement in clinical trials has been lacking but as involvement becomes more commonplace, the resulting changes could be abrupt and dramatic.
What is needed, she concluded, is leadership from each of the stakeholders involved in clinical research. Each group needs to ask how it is impeding the flow of information and the conduct of research and take steps to remove those barriers. Each needs to move forward, said Terry, “for the sake of all the people who need us to do this quickly, efficiently, and carefully.”